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anglais
BACKGROUND: Few data are available on the long-term outcome of noninvasive
positive pressure ventilation (NPPV) for obesity hypoventilation syndrome (OHS).
This study was designed to determine long-term survival, treatment adherence, and
prognostic factors in patients with OHS in whom NPPV was initiated in an acute
setting vs under stable clinical conditions.METHODS: One hundred thirty
consecutive patients with OHS (56 women) who started NPPV between January 1995
and December 2006 either under stable conditions (stable group, n = 92) or during
ICU management of acute hypercapnic exacerbation (acute group, n = 38) were
retrospectively analyzed. RESULTS: Arterial blood gases and the Epworth sleepiness
scale were both significantly improved after 6 months of NPPV. With a mean follow-
up of 4.1 +/- 2.9 years, 24 (18.5%) patients died and 24 (18.5%) discontinued NPPV.
On Kaplan-Meier analysis, 1-, 2-, 3-, and 5-year survival probabilities were 97.5%,
93%, 88.3%, and 77.3%, respectively. Mortality was lower than that described in a
previous series of patients with untreated OHS. Supplemental oxygen therapy was
the only independent predictor of mortality. The probability of continuing NPPV was
80% at 3 years with a high rate of daily use ( > 7 h). Female sex was predictive of
lower long-term adherence to NPPV. The acute and stable groups did not differ in
terms of arterial blood gases and Epworth sleepiness scale at 6 months, long-term
survival, and treatment adherence. CONCLUSIONS: The results of this study
support long-term NPPV as an effective and well-tolerated treatment of OHS
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